Sacituzumab tirumotecan Cuts Tumor Progression 65%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sacituzumab tirumotecan cut tumor progression risk by 65% in a Phase 3 trial of patients with previously untreated advanced non‑small‑cell lung cancer.
- Kelun‑Biotech developed the antibody‑drug conjugate and licensed it to Merck, enabling the first successful ADC‑PD‑1 combination in this patient group.
- The study conducted in China also reported a preliminary overall‑survival benefit, though longer follow‑up is required to confirm the finding.
Why it matters: Patients with advanced NSCLC gain a therapy that dramatically delays progression, while Merck and Kelun‑Biotech stand to capture a sizable share of the $8 billion lung‑cancer market, prompting insurers to reassess treatment guidelines.
Ask SkimNews
